Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells

Goya, Rodolfo G.; Rowe, Joanna; Sosa, Yolanda E.; Tomašec, Peter; Löwenstein, Pedro R.; Castro, María G.

doi:10.1016/s0303-7207(98)00059-8

Cited by 23 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, it was shown that tsK/b-gal ef®ciently transduced all endocrine AP cells in vitro, including lactotrophic and somatotrophic cells (3). Here, we expanded these studies by assessing transgene expression in the adenohypophysis in vivo.…”

Section: Pituitary Transgene Expression In Vivomentioning

confidence: 95%

“…Adenoviral and herpetic vectors were successfully used to transfer different genes into normal and neoplastic anterior pituitary (AP) cells in culture (2±8). Moreover, adenoviral vectors have been used to transfer in vivo the herpes simplex virus type 1 (HSV-1)-thymidine kinase (TK) suicide gene to somatomammotrophic tumour cells (GH 3 ) grafted into nude mice as well as to oestrogen-induced rat lactotrophic tumours (6±8).…”

Section: Introductionmentioning

confidence: 99%

“…As protein ICP4 is fully active at 31 8C, tsK mutants are replication competent at this permissive temperature (9,10). Using the tsK/b-gal vector, it has been previously shown that this kind of vector is capable of transducing pituitary-derived cell lines (AtT20 and GH 3 ) as well as normal AP cells in vitro (3). Recently, another tsK-derived vector, tsK/CRH10, expressing the rat corticotrophin-releasing hormone precursor (preproCRH (ppCRH)) was constructed.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion

Bolognani

Albariño

Romanowski

et al. 2001

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Herpes simplex virus type 1 (HSV-1)-derived vectors are known to be effective tools to deliver transgenes into normal and neoplastic anterior pituitary (AP) cells in vitro. Our objective was to assess the in vitro and in vivo effects of tsK/b-gal, a temperature-sensitive HSV-1-derived vector harbouring the E. coli b-galactosidase gene, on AP hormone secretion as well as on transgene expression in rat AP tumours (hyperplastic prolactinomas). Design: The impact of vector infection on prolactin (PRL) and GH release was determined in vitro in normal and hyperplastic (lactotrophic) dispersed AP cells exposed for 24 h to tsK/b-gal as well as in vivo in ectopic AP grafts. In some oestrogen-induced prolactinoma-carrying rats, vector suspension was stereotaxically injected into the glands to assess transgene expression in vivo. Methods: GH and PRL release was measured by speci®c RIAs. In vivo transgene expression was assessed by immunohistochemistry for b-galactosidase and enzymohistochemistry (5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside). Ectopic pituitary grafts and stereotaxic surgery were performed following standard procedures. Results: At a multiplicity of infection of 0.5, the vector induced a 30 and 22% fall in PRL and GH release respectively in normal AP cells, whereas the corresponding hormone release inhibition for hyperplastic AP cells was 41 and 33% for PRL and GH respectively. In ectopic pituitary grafts, the effect of vector infection on hormone secretion was assessed by measuring serum PRL levels in the host rats every 5 days for 4 weeks post-grafting. In the pituitary-grafted rats that received the viral vector, serum PRL failed to increase to the levels achieved in control-grafted animals. Finally, pituitary tumours stereotaxically injected with tsK/b-gal showed widespread expression of the b-galactosidase transgene around the injection areas. Conclusions:The results reported here have implications for basic studies using gene transfer to pituitary gland as well as potential gene therapy approaches to pituitary diseases.

show abstract

Section: Pituitary Transgene Expression In Vivomentioning

confidence: 95%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion

Bolognani

Albariño

Romanowski

et al. 2001

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…2), as well as into the corticotropic AtT 20 and somatomammotropic GH 3 tumor cell lines [19, 20]. Interestingly, neoplastic AP cells were found to be more susceptible to viral vector-mediated transduction than normal AP cells.…”

Section: Gene Therapy In Pituitary Tumorsmentioning

confidence: 99%

Gene Therapy in the Neuroendocrine System: Its Implementation in Experimental Models Using Viral Vectors

Bolognani

Goya²

2001

Neuroendocrinology

View full text Add to dashboard Cite

Gene therapy, the transfer of genetic material for therapeutic purposes, has undergone an explosive development in the last few years. Within this context, development of gene therapy approaches for the neuroendocrine system, while incipient, has already generated a core of results which emerge as a promising area of research in neuroendocrinology. The present review presents a brief description of the viral vector-based gene delivery systems being currently used in neuroendocrinology, namely the adenoviral and herpes simplex type-1 (HSV-1)-derived vector systems, as well as an updated account of neuroendocrine pathologies for which gene therapy approaches in animal models are being implemented is provided. Current research efforts include treatment of experimental pituitary tumors by adenoviral vector-mediated transfer of the suicide gene for the HSV-1 thymidine kinase, which converts the prodrug ganciclovir into a toxic metabolite. An adenoviral vector encoding the human retinoblastoma suppressor oncogene has also been successfully used to rescue the phenotype of spontaneous pituitary tumors of the pars intermedia in mice. At the hypothalamic level, an adenovirus harboring the cDNA for arginine vasopressin has been used in Brattleboro rats to correct diabetes insipidus for several weeks. The last part of the review outlines the potential of gene therapy to correct age-associated neurodegenerative processes at the neuroendocrine level. Although effective implementation of gene therapy strategies still faces significant technical obstacles, these are likely to be progressively overcome as gene delivery systems are being improved.

show abstract

“…To achieve cell-specific gene expression in pituitary cells, various strategies have been followed, including direct injection of vectors into the pituitary, the use of pituitary-specific promoters (GH, proopiomelanocortin, PRL, or glycoprotein hormone α-subunit promoters) to ensure targeted expression, and Cre-mediated recombination to activate repressive promoters in a cell-specific manner. Another possibility is retargeting viral vector tropism, so that the vectors specifically bind to hypothalamic hormone receptors that are over expressed in pituitary tumors [14,15]. Although recombinant temperature-sensitive Herpes simplex virus (HSV)Type 1 vector is an efficient delivery system that can be used to transfer genes into tumors and normal anterior pituitary cells, the neurovirulence of this vector limits its potential use in humans [16].…”

mentioning

confidence: 99%

Gene therapy in endocrine tumors: A comprehensive overview [Review]

2014

View full text Add to dashboard Cite

Use of recombinant herpes simplex virus type 1 vectors for gene transfer into tumour and normal anterior pituitary cells

Cited by 23 publications

References 17 publications

In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion

In vitro and in vivo herpetic vector-mediated gene transfer in the pituitary gland: impact on hormone secretion

Gene Therapy in the Neuroendocrine System: Its Implementation in Experimental Models Using Viral Vectors

Gene therapy in endocrine tumors: A comprehensive overview [Review]

Contact Info

Product

Resources

About